U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

Read also:

• Evidence piles up that Trump's tariffs are crushing job market - Daily Kos
• Real-World GLP-1 Weight-Loss Results Differ From Trials - Medscape
• What are your thoughts on a Russian poetry prize banning entries from transgender people? Why is Russia so transphobic?
• Why do atheists love to preach against Abrahamic religions and mock God? Even if they do not fear the eternal fire of hell, pious Muslims will certainly not leave them alone and will take brutal revenge until they surrender and repent of their sins.
• New Apple study challenges whether AI models truly “reason” through problems - Ars Technica
• What are the most common misconceptions people have about demon summoning?
• Do women lack the mental strength to succeed at STEM? There seems to be few women at STEM and more women leave STEM after a time of working at it. How can it be just sexism if women aren't banned from entering?
• How do people in other countries view Trump's trade policies and their impact on the global economy?
• Teens like me, what are your expectations when entering adulthood?
• Why did Meghan become a Hollywood actress before marrying into royalty? Was this against protocol and tradition for future royals who marry into the UK monarchy?